$10.340
-0.853 (-8.25%)Al cierre
Noticias de ARCT
Eventos de ARCT
Arcturus Signs Agreement to Acquire myNEO
The company states: "Arcturus has entered into a definitive agreement to acquire myNEO, subject to customary closing conditions. The transaction is expected to close in October. Arcturus has been working closely with myNEO since 2024. The acquisition brings a differentiated computational engine, supported by proprietary intellectual property, intended to fortify Arcturus' AI infrastructure by improving mRNA design quality and enhancing target identification capabilities."
Arcturus Therapeutics Announces Encouraging Interim Phase 2 Results for ARCT-810 and Launches LUNAR 2.0
The company states: "Arcturus Therapeutics announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase deficiency and introduced LUNAR 2.0, the Company's next-generation mRNA delivery platform, and additional liver pipeline programs. In the Phase 2 study to date, ARCT-810 was generally safe and well tolerated, reduced and/or maintained first morning fasting ammonia within the normal range, including during increases in protein intake by participants; reduced glutamine, with participants at the 0.5 mg/kg dose level achieving mean glutamine values within the normal range during treatment. Weight gain was observed in all participants." "The ARCT-810 Phase 2 interim results validate Arcturus' mRNA liver therapeutics platform and the introduction of LUNAR 2.0 marks the beginning of a new and exciting chapter for Arcturus," said Joseph Payne, President and CEO of Arcturus. "We are very pleased that ARCT-2601, utilizing LUNAR 2.0, is positioned to be efficiently integrated into our ongoing OTC deficiency Phase 2 study later this year."
Arcturus Announces Strategic Collaboration with Thermo Fisher
Arcturus Therapeutics (ARCT) announced a strategic collaboration with Thermo Fisher Scientific (TMO) to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus' investigational mRNA therapy for Cystic Fibrosis. The collaboration will leverage Thermo Fisher's Accelerator Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher will provide integrated manufacturing, clinical research, and commercial readiness services to help accelerate development of ARCT-032 while Arcturus continues to advance the program. Under the agreement, Thermo Fisher will provide Phase 3 manufacturing, clinical research, and related services. If Phase 2 yields positive results, Arcturus expects to conduct its Phase 3 program through Thermo Fisher's PPD(TM) clinical research business. Subject to regulatory approval of ARCT-032, Thermo Fisher will receive exclusive commercial manufacturing rights under a separate commercial agreement.
Arcturus Q1 Revenue $2.1M, Below Consensus
Reports Q1 revenue $2.1M, consensus $6.9M. "Arcturus continues to advance its rare disease therapeutics portfolio. We have initiated enrollment of our 12-week CF Phase 2 study in the first quarter of 2026, earlier than originally anticipated. We remain committed to advancing our inhaled mRNA therapy for people with CF Class I mutations," said Joseph Payne, President & CEO of Arcturus. "Also, during the first quarter of 2026, we met with the FDA regarding the pediatric clinical development strategy for our OTC deficiency program and we now have a clear path toward initiating a pivotal trial which we will align further at the EOP2 meeting later this year. We welcomed two seasoned C-suite leaders, Alan H. Cohen, MD, Chief Medical Officer and Dennis M. Mulroy, Chief Financial Officer to strengthen the executive team."
Arcturus Q4 Revenue $7.2M, Below Consensus
Reports Q4 revenue $7.2M, consensus $14.32M. "Arcturus continues to progress its rare disease therapeutic portfolio. We look forward to aligning with regulators on our clinical development strategy for the ornithine transcarbamylase (OTC) deficiency program, and to initiating our Phase 2, 12-week cystic fibrosis (CF) study in the first half of 2026," said Joseph Payne, President & CEO of Arcturus. "We remain firmly committed to advancing our once-daily inhaled mRNA therapy for people with cystic fibrosis Class I mutations."
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.